IP Verse

Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel Gmbh opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel Gmbh

Patent Number:
EP2959894
Title:
S1P Receptor Modulators For Treating Multiple Sclerosis
Applicant:
NOVARTIS AG
Opposition Date:
Jul 12, 2023
Patent Number:
EP2493466
Title:
Novel Antitumoral Use Of Cabazitaxel
Applicant:
AVENTIS PHARMA S.A.
Opposition Date:
Mar 31, 2021
Patent Number:
EP3294285
Title:
Cabazitaxel And Its Use For Treating Cancer
Applicant:
AVENTIS PHARMA S.A.
Opposition Date:
Aug 26, 2020
Patent Number:
EP3351246
Title:
Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated Angiogenesis
Applicant:
NOVARTIS AG
Opposition Date:
Jan 29, 2020
Patent Number:
EP3342411
Title:
Rapamycin Derivative For Treating Pancreas Cancer
Applicant:
NOVARTIS AG
Opposition Date:
Aug 27, 2019
Patent Number:
EP3078667
Title:
Formulation Of Boronic Acid Compounds
Applicant:
THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Opposition Date:
Aug 20, 2019

Competitors of Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel Gmbh

NOVARTIS AG

AVENTIS PHARMA S.A.

NOVARTIS INTERNATIONAL PHARMACEUTICAL AG

Want to track Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel Gmbh?

Feel free to send us a message here and we will get back to you